Kantar Health Blog

  • New MOAs in Multiple Myeloma Shine at ASH 2012

    by Stephanie Hawthorne | Dec 10, 2012
    Stephanie Hawthorne
    Oncology Conference Insight Blog from ASH 2012: The multiple myeloma landscape is rapidly evolving, with the recent approval of Kyprolis (carfilzomib, Onyx) and the pending approval of pomalidomide (Celgene), both in the relapsed/refractory setting. We’ll see pivotal data for pomalidomide on Tuesday morning during ASH’s Late-Breaking Abstract session, but the first days of the conference have highlighted a few new mechanisms of action that are showing promising activity in multiple myeloma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blog from SABCS 2012 Adjuvant therapy is improving outcomes in breast cancer and that can always be considered a positive result. Also, those patients who may be ineligible for aromatase inhibitors, will be able to benefit from the new 10-year tamoxifen standard of care. It is clear that long-term follow-up is the key for getting the most out of these adjuvant therapy studies.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blog: SABCS 2012 With Afinitor recently approved in combination with hormone therapy and pursuing development in the adjuvant setting, and PD 0332991 now demonstrating highly meaningful clinical activity in ER+ patients, we are at the dawn of a new era in breast cancer that could have significant impact on the future course of the disease.
    Continue Reading > | Go comment! | Share
  • Richard Martin
    Who will respond? What course of treatment should be undertaken? Why should we do more than standard treatment and palliative care when there are uncertain outcomes and the pursuit of those uncertain outcomes is increasingly expensive? How do we allocate resources? When do we stop trying to sustain life and instead make the remaining life the most comfortable and satisfying under the circumstances?
    Continue Reading > | Go comment! | Share
  • User Not Found
    Most practices have weathered the storm of declining drug reimbursement. Patient volumes remain strong and reimbursement appears to be stable or positive. Practices generally report slow growth toward expansion and ongoing efficiency improvements. However, options for service diversification appear to be narrowing, with large practices likely to have added services requiring capital investment already. Overall, minor modifications to practice operations continue as practices actively explore new ways to remain competitive.
    Continue Reading > | Go comment! | Share